A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
Public ClinicalTrials.gov record NCT06381583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Liquid Biopsy to Screen for Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: the EMERALD Multi-center Study.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.
Study identification
- NCT ID
- NCT06381583
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 658 participants
Conditions and interventions
Conditions
- Esophagus Cancer
- Esophageal Cancer Stage
- Esophageal Cancer
- Esophageal Neoplasms
- Esophagus Adenocarcinoma
- Esophagus, Barrett
- Barrett Esophagus
- Barrett Adenocarcinoma
- Barrett Epithelium
- Barretts Esophagus With Dysplasia
- Barrett's Esophagus Without Dysplasia
- Barretts Esophagus With High Grade Dysplasia
- Barretts Esophagus With Low Grade Dysplasia
- Barrett Esophagus, Long-Segment
- Barrett's Esophagus With Dysplasia, Unspecified
- Barrett's Esophagus With Esophagitis
- Gastroesophageal Reflux
- Reflux Disease
- Esophageal Adenocarcinoma
- Esophageal Dysplasia
- Esophageal Neoplasms Malignant
Interventions
- EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) Diagnostic Test
Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2023
- Primary completion
- Apr 23, 2024
- Completion
- Apr 23, 2024
- Last update posted
- May 9, 2024
2023 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06381583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2024 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06381583 live on ClinicalTrials.gov.